The European Partnership European Rare Diseases Research Alliance (ERDERA) has open its call for international projects “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”. Deadline for pre-proposals is 13. 2. 2025. Participation of Czech entities will be funded via the Czech Health Research Council (AZV). On 17. 12. 2024, ERDERA organise a webinar for applicants. Event webpage and registration. On 19. 12. 2024, AZV organise a webinar for Czech applicants in calls of European Partnerships (probably in Czech). Registration is open until 17. 12. 2024, inclusive. About the event and registration. If you plan to participate in a proposal, please, contact well in advance, 1 month before the deadline at the latest, the Project Management Department (Ludmila Součková, ludmila.souckova@natur.cuni.cz), so that all the formal requirements of the application can be prepared in time. If you consider coordinating a project, please contact us IMMEDIATELY, ca. 2 months before the deadline at the very latest. About the call announcement on ERDERA website. ERDERA information for joint transnational calls – call documentation, timeline, key links etc. Call text – supported topics, eligibility criteria, participating countries etc. About the call on AZV website – key information and documents for Czech applicants. Conditions for Czech applicants (in Czech). Proposals must cover at least two of the following areas: Development of novel therapies in a pre-clinical setting through cell, organoid and animal disease model studies, and/or use of in silico or artificial intelligence models to accelerate the success rate of the pre-clinical stage Development of predictive and pharmacodynamics biomarkers correlated to the efficiency of the therapy in a preclinical setting that could serve as surrogate endpoints Replication of pre-clinical studies in an independent lab to increase validity of exploratory findings Pre-clinical proof of concept studies for evidence of pharmacological activity in vitro and in vivo, pharmaco-kinetics and pharmaco-dynamics of the investigational drug (i.e., small molecule(s) and/or biologic) and first toxicology and safety data as well as studies to support readiness for initiating clinical trial authorization conforming to regulatory requirements Project duration is up to 3 years. Project consortium must consist of 4–6 partners (principal investigators) from at least 4 countries participating in the call. At least one partner must be an “Early Career Researcher” (a researcher who has received their PhD, or a medical doctor who has completed their specialist medical training, no more than 7 years before the application deadline). Maximal number of partners is increased to 8, if the 1–2 “additional” partners are additional “Early Career Researcher” or are from one of the “underrepresented countries” (e.g., Czechia). No more than 2 partners from 1 country can participate in one proposal. Each partner must fulfil the eligibility criteria of their national funding body. Countries participating in the call: Austria, Belgium, Bulgaria, Canada, Cyprus, Czechia, Denmark, Estonia, France, Germany, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, Netherlands, Türkiye. Funding of participation of Czech entities will be linked to the Applied Health Research Support Program for 2024 – 2030, Sub-programme 3: European Partnerships in Health. Only applied research will be supported. Total financial allocation for Czech participation in this call is EUR 500 000, maximal funding for the Czech part of one project is EUR 250 000. Maximal funding rate for Czech participants in case of research organisations is up to 100 %. The proposals are submitted by the coordinator on behalf of the entire consortium via the electronic submission system. Czech participants must simultaneously submit to AZV the compulsory national application annexes. Submission of the national annexes via data box of Charles University and some of the annexes themselves will be secured by the Project Management Department. Therefore, it is essential for applicants to contact us well in advance (at ludmila.souckova@natur.cuni.cz). News published by Ludmila Součková on 11. 12. 2024.Updated 12. 12. 2024 (conditions for Czech applicants added).Updated 20. 1. 2025 (Slovenia added to the list of participating countries). Not the information you sought? Found a mistake? Please, let us know. Přehled všech grantových aktualit All current funding news Newsletter„Grantové informace” “Funding Opportunities” newsletter